NCHR Testimony on the Opioid Buprenorphine/Samidorphan for Depression

November 1, 2018. The clinical trial data do not provide adequate evidence that buprenorphine/samidorphan reduces the symptoms of depression. There are concerns about it potential for long-term harms to patients and others who might misuse or abuse it. BUP/SAM needs to provide strong evidence of efficacy before approval.

Read More »
Page 5 of 107« First...34567...102030...Last »